STERIS (STE)
(Delayed Data from NYSE)
$234.73 USD
-1.05 (-0.45%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $234.79 +0.06 (0.03%) 5:28 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$234.73 USD
-1.05 (-0.45%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $234.79 +0.06 (0.03%) 5:28 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Steris (STE) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 10.90% and 1.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stock Earnings on Feb 2: IDXX, MCK & More
by Urmimala Biswas
In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefits from pharma customers on growing vaccines, along with a recovery in the Healthcare arm in Q3.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) to Expand Product Suite Via Cantel Medical Buyout
by Zacks Equity Research
STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.
Why Is Steris (STE) Up 10% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS
by Zacks Equity Research
Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Steris (STE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 19.35% and 7.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Earnings Due on Nov 2: STE, HSIC & More
by Urmimala Biswas
Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
Analysts Estimate Steris (STE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Steris (STE) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Steris (STE) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 35.05% and 4.55%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
Analysts Estimate Steris (STE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes
by Zacks Equity Research
As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.
STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.
Steris (STE) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 4.46% and 4.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for May 13: SDC, STE & More
by Urmimala Biswas
Many medical product companies register strong earnings growth in Q1, riding on huge market adoption of their COVID-19-related support products and growing demand for non-elective procedures.
Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.